CRDL Cardiol Therapeutics Inc - Ordinary Shares - Class A
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
22
Frequently Asked Questions
What is Market Cap of Cardiol Therapeutics Inc - Ordinary Shares - Class A?
What is the 52-week high for Cardiol Therapeutics Inc - Ordinary Shares - Class A?
What is the 52-week low for Cardiol Therapeutics Inc - Ordinary Shares - Class A?
What is Cardiol Therapeutics Inc - Ordinary Shares - Class A stock price today?
What was Cardiol Therapeutics Inc - Ordinary Shares - Class A stock price yesterday?
What is the PE ratio of Cardiol Therapeutics Inc - Ordinary Shares - Class A?
What is the Price-to-Book ratio of Cardiol Therapeutics Inc - Ordinary Shares - Class A?
What is the 50-day moving average of Cardiol Therapeutics Inc - Ordinary Shares - Class A?
How many employess does Cardiol Therapeutics Inc - Ordinary Shares - Class A has?